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Background: Tuberculosis (TB), is caused by the bacteria, Mycobacterium tuberculosis and its a threat to humans
since centuries. Depending on the type of TB, its treatment can last for 6–24 months which is a major cause for
patients non-compliance and treatment failure. Many adverse effects are associated with the currently available TB
medicines, and there has been no new anti-tuberculosis drug on the market for more than 50 year, as the drug
development is very lengthy and budget consuming process.
Development of the biocompatible nano drug delivery systems with the ability to minimize the side effects of the drugs,
protection of the drug from enzymatic degradation. And most importantly the drug delivery systems which can
deliver the drug at target site would increase the therapeutic efficacy. Nanovehicles with their tendency to release
the drug in a sustained manner would result in the bioavalibilty of the drugs in the body for a longer period of time
and this would reduce the dosing frequency in drug administration. The biocompatible nanovehicles with the
properties like sustained release of drug of the target site, protection of the drug from physio-chemical degradation,
reduction in dosing frequency, and prolong bioavailability of drug in the body would result in the shortening of the
treatment duration. All of these factors would improve the patient compliance with chemotherapy of TB.
Result: An anti-tuberculosis drug, 4-amino salicylic acid (4-ASA) was successfully intercalated into the interlamellae of
zinc layered hydroxide (ZLH) via direct reaction with zinc oxide suspension. The X-ray diffraction patterns and FTIR
analyses indicate that the molecule was successfully intercalated into the ZLH interlayer space with an average basal
spacing of 24 Å. Furthermore, TGA and DTG results show that the drug 4-ASA is stabilized in the interlayers by
electrostatic interaction. The release of 4-ASA from the nanocomposite was found to be in a sustained manner. The
nanocomposite treated with normal 3T3 cells shows it reduces cell viability in a dose- and time-dependent manner.
Conclusions: Sustained release formulation of the nanocomposite, 4-ASA intercalated into zinc layered hydroxides,
with its ease of preparation, sustained release of the active and less-toxic to the cell is a step forward for a more
patient-friendly chemotherapy of Tuberculosis.
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Tuberculosis (TB) is one of the transmittable diseases
caused by the bacteria, Mycobacterium tuberculosis. Des-
pite the technological advancements, tuberculosis is still
lethal and the main cause of the human deaths in many
countries around the world. According to the latest facts
and figure about TB in the Global tuberculosis report
2012, there were about 8.7 millions new cases of TB in
2011 and 1.4 million humans lost their lives. TB is one
of the top killers of women, with 300 000 deaths among
HIV-negative women and 200 000 deaths among HIV-
positive women in 2011 [1].
There are three forms of TB, namely drug susceptible-,
multidrug resistant- and extensively resistant-TB. Drug sus-
ceptible TB is mainly treated with first line anti-TB drugs
such as Rifampin, Isoniazid, Ethambutol and Pyrazinamide,
and treatment usually lasts from 6–9 months.
When tuberculosis bacteria develop resistance to at
least two most powerful first line drugs Rifampicin
(RMP) and Isoniazid (INH), it is called multi-drug re-
sistant tuberculosis (MDR-TB) [2]. MDR-TB patients'
treatment can last for 20 months [3]. 4-amino salicylic
acid is a bacteriostatic agent and is extremely helpful in
controlling the growth of bacteria. It is also very useful
in avoiding the development of the resistance of bac-
teria to the other anti-MDR-TB drugs [4]. MDR-TB pa-
tients have to take 4 g dose of 4-ASA twice daily
during treatment [4]. As we know that the drug devel-
opment is a time consuming process and requires a
huge amount of budget and no new anti-TB drug has
been introduced in the market for almost 50 years,
therefore, the logical approach in such circumstances is
that we should use the currently available drugs more
intelligently and effectively.
4-aminosalicylic acid (4-ASA) was introduced in 1948
in clinical trials and was found to be very effective against
TB [5]. However, due to its side effects such as anorexia,
epigastria distress, nausea, vomiting, abdominal cramps
or diarrhea, it is no longer used for drug susceptible TB,
but is used for the multi-drug resistant TB and Con-
trolled release formulation would be very useful to resuce
the side effects associated with 4-ASA [6,7]. In order to
avoid these side effects associated with 4-ASA, various
strategies have been adopted by physicians such as the
drug given in the form of buffered tablets, granules, coated
tablets and salt of acid. The intrinsic half-life of 4-ASA is
45–60 min. The controlled and targeted release can be the
best choice to avoid the side effects and would also in-
crease the intrinsic half life of the drug. The sustained re-
lease formulation would not only minimize the side effects
but would also result in the shortening of the treatment
duration and also the dosing frequency. The reduction in
the frequency of the dose administration would enhance
the patient compliance to the treatment.Keeping this idea in mind, we have developed the
controlled release formulation of 4-amino salicylic acid
(4-ASA) with zinc layered hydroxides.
There have been many attempts made earlier by vari-
ous scientists in the development of drug delivery sys-
tems for anti-tuberculosis drugs. Inhalable microparticles
of polylactic acid, mannitol microparticles, glucan parti-
cles (GPs) and plant proteins etc., have been developed
for the delivery of anti-TB drugs, a good review was writ-
ten by Saifullah et al. Which discusses many of these de-
livery systems in detail [8].
Zinc layered hydroxide (ZLH) has the structure similar
to that of brucite (Mg (OH)2 which is a hydrotalcite-like
compound and is formed by a layered unit with the
metal cations octahedrally coordinated with hydroxyl
groups. A quarter of the octahedral of zinc cation coordin-
ation is displaced from the main layer to tetrahedral sites
located above and below each empty octahedron and can





Am−ð Þx=m:nH2O , where M2+ is diva-
lent cations, M3+ is trivalent compound and Am- is an ex-
changeable anion, with the charge, (m-) [9].
Characteristics of zinc layered hydroxides are similar
to that of layered double hydroxides which have plenty
of benefits as a drug delivery system, such as their ease
of laboratory preparation with controlled particle size
[10]. The drugs can easily be accommodated in the
space of interlayers by ion exchange as compared to the
other nanoparticles which need surface modification i.e.
functionalization of the surface [11,12].
ZLH, have high zeta potential, 20–30 mV like to that
of the layered double hydroxides, which is a strong driv-
ing force onto the surface of the cell. On the other hand,
other inorganic nanoparticles, due to their low solubility,
they accumulated in cells. The biocompatibility, con-
trolled release and easier degradation without accumula-
tion in the body are important characteristic of the
layered double hydroxides and zinc layered hydroxides,
which make them strong candidates as drug delivery sys-
tems. In previous studies it has been reported, that the
Zn-Al LDH does not show any toxic effect on Chinese
hamster ovary cells at low concentration [13]. ZLH has
also been used as a drug delivery system of an anticancer
compound, ellagic acid [14]. The intercalation of hip-
puric acid into ZLH has resulted in the less toxic of the
compound compared to the pure hippuric acid itself
[15]. It was also reported that the controlled release for-
mulation of an antihistamine was obtained by forming
the cetirizine-ZLH nanocomposite [16].
In this study, we report a controlled release formula-
tion of 4-amino salicylic acid, an antituberculosis agent
by forming a nanocomposite zinc layered hydroxides
(4-ASA-ZLH) nanocomposite.






























Figure 1 Powder X-ray diffraction results patterns for the zinc
oxide (A), ASA-nanocomposite in which the symbol * represent
zinc oxide peaks and triangle shows the adsorbed drug on the
layers (B) and free 4-amino salicylic acid (C).
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Materials
Analytical grade chemicals were used without any further
purification. 4- amino salicylic acid 99% purity and zinc
oxide were purchased from Sigma-Aldrich. Dimethyl
sulfoxide (DMSO) was used as solvent and was pur-
chased from Ajax Finechem (Sydney, Australia) with
0.1% water content.
Synthesis
The drug, 4-aminosalicyclic acid (0.4 mol) was mixed into
50 mL (i.e 25 mL Deionized water and 25 mL DMSO)
and was stirrer for 20 minutes at room temperature.
About 0.2 g zinc oxide was mixed with 50 ml deionized
water and stirred for 25 minutes. The drug solution
was added drop wise into zinc oxide suspension, and
the pH of the final solution was raised to 7.9 by drop
wise addition of 0.5 M sodium hydroxide solution. The
solution was kept on stirring for 18 hours at 70°C. The
sample was centrifuged and washed with deionized water
and kept in an oven at 70°C for 48 hours and the sample
was then subjected to further characterizations [14,17-18].
Controlled release study
The release of 4-aminosalicylic acid was performed on dif-
ferent human body simulated pH 4.8 and 7.4 buffer solu-
tions (0.1 M). The phosphate-buffered solution contains a
number of anions, such as Cl−, monobasic phosphate
H2PO4
−, and dibasic phosphate HPO4
2−. About 0.6 mg of
the nanocomposite was placed into 3.5 mL of either a pH
4.8 or pH 7.4 buffer solution. The absorbance were mea-
sured at λmax = 268 nm [19] by a UV–vis absorption
spectrophotometer.
To compare the release of 4-aminosalicylic acid from
nanocomposite and from a physical mixture of 4-
aminosalicylic acid with ZLH, a specific amount of the
physical mixture of 4-aminosalicylic and the pristine ZLH
was used. The release of the active, 4-aminosalicylic was
determined as previously described above.
Cell culture
Healthy 3T3 mouse fibroblast cells were obtained
from ATCC (USA). 3T3 fibroblast cells were cultured
at 37°C and 5% CO2 in high glucose Dulbecco’s Modified
Eagle Medium containing 10% fetal bovine serum, 0.5%
penicillin–streptomycin, 1% glutamine, and 1% non-
essential amino acids. Cultured cells were passaged
using 0.25% trypsin. At 80% confluence, cultured cells were
harvested using 0.25% trypsin and were subcultured/
seeded in 96-well plates for further characterizations.
Assessment of cytotoxicity by MTT assay
Cytotoxicity of synthesized nanocomposites was evaluated
by MTT assay, where the cell viability is spectroscopicallymeasured as the total mitochondrial activity. For MTT
assay, cultured 3T3 cells were seeded and cultured in a 96-
well culture plate (at a density of 1 × 104 cells per well) in
100 μL cell culture medium (DMEM with 10% fetal bovine
serum) and the same were incubated for 24 hours under
cultured conditions at 37°C and 5% CO2. Then, cultured
cells were washed with phosphate-buffered saline (PBS, pH
7.4) and were then incubated with a medium (100 μL)
containing dispersed nanocomposite in various gradient
concentrations, range from 0.781 μg/mL to 50 μg/mL.
Cells not exposed to nanocomposite were served as con-
trol in each experiment. After 24, 48 and 72 hours of incu-
bation, the medium were removed from 96 well plate and
incubated with 100 μLof the freshly prepared MTT reagent
in DMEM for another 3–4 hours. Observance of the solu-
tion in 96 well plates was measured at 570 NM using a
microplate reader. Data are expressed as the percentage of
cell viability compared with untreated cells under the same
experimental conditions.
Characterization
Shimadzu XRD-6000 diffractometer (Tokyo, Japan) was
used to obtain the powder X-ray diffraction (PXRD)
Figure 2 Spatial Orientation of 4-ASA three-dimensional structure of 4-amino salicylic acid (A) and molecular structural models of 4-
amino salicylic acid intercalated between interlamellae of ZLH (B).




























Figure 3 FTIR Spetra of free 4-amino salicylic acid (A) and
4ASA-nanocomposite (B).
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for recording the PXRD difractograms between 2-60o.
Fourier transform infrared (FTIR) spectra of the mate-
rials were recorded over the range of 400–4000 cm-1 on
a Perkin- Elmer 100 series spectrophotometer by direct
sample method. A LECO, model CHNS-932 instrument
(St Joseph, MI) was utilized for the analysis of carbon,
hydrogen, nitrogen and sulfur (CHNS). A Mettler
Toledo instrument (Greifensee, Switzerland), was used
for the thermo gravimetric and differential thermo gravi-
metric analyses (TGA-DTG) analysis. Micromeritics
ASAP 2000 (Norcross, GA), was used for the surface
area analysis of the samples, by nitrogen gas adsorption–
desorption method at 77 K. For the determination of the
morphology of the sample surface, a scanning electron
microscope (SEM), JOEL JSM-6400 (Tokyo, Japan)
was used. A Perkin Elmer UV–vis Spectrophotometer-
Lambda was used to determine UV–visible spectra for the
optical properties and controlled release studies.
Results and discussion
Powder X-ray diffraction
Figure 1A, B, and C shows the powder X-ray diffraction
patterns for zinc oxide, 4-ASA-nanocomposite, and free
4-amino salicylic acid, respectively. As reported in the
literature, the zinc layered hydroxide with nitrate as the
counter anions can be prepared by adding the sodium
hydroxide to zinc nitrate hexahydrate solution. This
preparation give a sharp reflection peak with d-spacing,
9.74 Å at 2θ = 9.12 due to the 200 planes of the mono-
clinic structure [20].
Zinc oxide in aqueous solution formed ZLH layers and at
the same time intercalate the anions between the layers, as
was proposed earlier [21]. The layers of zinc hydroxide (Zn
(OH)2) were formed on the surface of the solid particles
due to hydrolyzed zinc oxide in an aqueous environment.The dissociation of Zn (OH) 2 in a solution-solid interface
produces Zn2+ species, which subsequently react with hy-
droxide group, drug anions and water in solution to form
drug-zinc layered hydroxide compound. The Figure 1A
shows five intense peaks between 30° and 60°, correspond-
ing to diffractions due to the 100, 002, 101, 102, and 110
planes which characteristic of ZnO.The presence of a peak
at a lower 2θ angle with d spacing of 25.2 Å indicates suc-
cessful intercalation of the 4-amino salicylate anions into
the interlayers of zinc-layered hydroxide (Figure 1B). The
resulting 4-ASA nanocomposite sample contains a little
amount of zinc oxide (indicated by a star). In addition,
Figure 1B shows another three harmonics at 2θ = 7.6°,





νas (N-H) 3490 Band for N-H symmetry and
antisymmetry are overlapped
with O-H stretching at 3345νs (N-H) 3381
ν (O-H) in the layer;
H2O
-
ν (C-C) 1649, 1519 1502
ν(C = O) in COOH 1609, 764 -
ν (O-H) ring 3020,1283, 1163 1162
δb (CH), in plane
bends
1220, 1109, 813 1200, 1027, 827





*unit for the given number is the wavenumber (cm-1).
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spectively, resulting in an average basal spacing value of
24.0 Å. Some of the 4-amino salicylate anions are also
adsorbed on the surface of zinc-layered hydroxide, which
are indicated by triangles in the XRD diffractogram of
the nanocompsite.
Spatial orientation of intercalated 4-amino salicylic acid
Figure 2A shows the three-dimensional molecular size
of 4-amino salicylic acid obtained using a Chemoffice
software 2008 (Cambridge, MA). The x, y and z axes of
4-amino salicylic acid was calculated and were found to
be 9.4 Å, 7.1 Å and 2.9 Å, respectively. The X-ray diffrac-
tion pattern shows the average basal spacing, d = 24.0 Å
for the 4ASA-nanocomposite. Taken into account that
the thickness of the ZLH layer is 4.8 Å [19], and zinc
tetrahedron has 2.6 Å thickness for each layer [22], there-
fore the gallery height of zinc layered hydroxide after the
intercalation processes is 14.0 Å (24.0 – 4.8 + (2 × 2.6 Å)).
The value is much similar to a double of the 7.1 Å axis
(14.2 Å), which suggests that the anions are accommodated
as an alternate bilayer.
Infrared spectroscopy
The existence of free 4-amino salicylic acid (4-ASA) and
the 4-ASA-ZLH-nanocomposite were further confirmedTable 2 Elemental chemical composition of free 4-amino salic
Sample Ca (%w/w) Na (%w/w) C/N Znb (%w/w) aniona (%w/w)
ZnO - - - (80.30) -
4-ASA 58.68 9.75 6.02 - -
4-ASAN 10.54 1.54 6.84 52.7 16.86
Value in the parentheses is a theoretical value, an estimated from CHNS analysis, bestimby FTIR study as shown in Figure 3A and B, respectively.
The FTIR spectra of free 4-amino salicylic acid show two
bands at 3490 and 3381 cm-1 due to the N–H asymmet-
ric and symmetric stretching modes, respectively. The
strongest absorption in the FTIR spectrum is observed at
1610 cm-1 which is due to the C=O stretching mode of
COOH group. Others bands are listed in Table 1.
The disappearance of a C=O stretching band in the
carboxylic group for free 4-amino salicylic acid after
intercalation confirms that the species that were inter-
calated into the ZLH layers are in the anionic form of
4-amino salicylic acid, i.e. 4-amino salicylate. A band at
1549 cm−1 is due to the vas(COO
−) mode, and another
band at 1372 cm−1 is due to the symmetric vibration of vs
(COO−). These two bands indicate that there is an inter-
action between 4-amino salicylate and ZLH layers. The po-
sitions and relative intensities of the other bands almost
coincide with those in the spectra of the free 4-amino sali-
cylic acid. A bands due to Zn–OH translation modes are
recorded below at 600 cm−1.
Table 1 FTIR assignments for 4-amino salicylic acid
and 4ASA-nanocomposite [23,24].
Elemental analysis
The elemental analysis (CHNS and ICP) of the product
is usually used as a direct evidence to confirm the inter-
calation of the drug into ZLH inorganic interlayers.
Table 2 shows that the C/N ratio for free 4-amino sali-
cylic acid is 6.02 and this value is smaller than the C/N
ratio of 4-ASA nanocomposite which is 6.8, indicating
possible contamination by carbonate species during the
preparation. Therefore, the loading of 4-amino salicylic
acid between the ZLH was calculated using the nitrogen
percentage, which gave 16.9%. The presence of the car-
bonate anions was confirmed by the presence of a broad
peak at low 2θ (2θ =11. 65o) in the XRD patterns.
Thermal analysis
The thermal behavior of 4-amino salicylic acid and 4ASA-
nanocomposite was examined using thermogravimetric and
differential thermogravimetric analyses (Figure 4). For 4-
amino salicylic acid (Figure 4A), two main thermal events
were clearly observed; the first one occurred in the region
of 101–150°C, attributable to dehydration of 4-amino sali-
cylic acid, corresponding to a sharp peak at 145°C with aylic acid and its nanocomposite





ated from ICP analysis.

















































































Figure 4 Thermograms of 4-ASA and 4ASA nanocomposite TGA-DTG thermograms of 4-amino salicylic acid (A) and 4ASA-nanocomposite (B).
Saifullah et al. Chemistry Central Journal 2013, 7:72 Page 6 of 11
http://journal.chemistrycentral.com/content/7/1/7231.4% weight loss. The second stage at 151–235°C is due to
thermal combustion of 4-amino salicylic acid [25], corre-
sponding to a strong peak at 227°C with a 67.7% weight
loss. Figure 4B shows that the thermal decomposition of
4ASA-nanocomposite progresses through three major
stages of weight loss, occurring at temperature maxima of
65°C, 248°C and 683°C with weight losses of 3.1%, 21.6%
and 8.7%, respectively. The first stage of weight loss in the
range of 39–138°C is due to the removal of physisorbed
water on the external surface of the layered double hydrox-
ide. The second weight loss is mainly due to combustion of
4-amino salicylic acid anions at 248°C. Increase in theFigure 5 FESEM Micrographs of ZnO and 4-ASA nanocomposite field
and 4-ASA nanocomposite (C and D).decomposition temperature of 4-amino salicylic acid from
227°C (for free 4-amino salicylic acid) to 248°C (for 4-
amino salicylic acid intercalated into the nanocomposite)
indicates better thermal stability of 4-amino salicylic acid in
the intercalated form than the free 4-amino salicylic acid.
This presumably is due to electrostatic attraction between
the negatively charged functional group of 4-amino salicylic
acid and the positively charged zinc layered hydroxide.
Surface properties
Figure 5 A-D show the morphology of starting material,
zinc oxide and its ZLH-4-ASA nanocomposite obtainedemission scanning electron micrographs of zinc oxide (A and B),















































Figure 6 Surface area Analysis Isotherms: (A) Adsorption- desorption isotherms and (B) BJH pore size distribution for zinc oxide and
4-ASA-ZLH nanocomposite.
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composition without any specific shape, and with vari-
ous sizes (Figure 5A and 5B). As shown in the Figure 5C
and 5D, there is a significant difference in the morph-
ology of the both samples; the 4-ASA nanocomposite
shows agglomerates of compact and non-porous struc-
ture which indicates the transformation of the zinc oxide
to the zinc layered hydroxide nancomposites. This result
is very similar to the morphology of other intercalated
compounds such as hippurate-zinc layered hydroxide
and hippurate-Zn/Al-LDH [26].
Figure 6 shows the nitrogen adsorption-desorption
isotherms of zinc oxide and 4-ASA nanocomposite. All
the adsorption isotherms are of Type IV according to
IUPAC classification, indicating mesoporous type mater-
ial (20–500 Å) [27].The volume adsorb increases slowly
at a low relative pressure in a range of 0.0-0.8, followed
by a rapid adsorption at a relative pressure more than
0.8. For the 4-ASA nanocomposite, the optimum uptake
is slightly higher than their corresponding starting ma-
terial, zinc oxide. The desorption branch of the hyster-
















Figure 7 Control Release Profiles I) Release profiles of a physical mixt
(II) Release profiles of 4-amino salicylic acid from the 4-ASA nanocom
profilesof 4-amino salicylic acid from the nanocomposite at pH 4.8.oxide, indicating different pore texture of the resulting
materials. This is due to modification of the pores as a
result of the intercalation process and formation of the
new nanocomposite [28]. Table 2 shows the BET surface
area of the zinc oxide and 4-ASA nanocomposite. As
shown in Table 2, the surface area of the resulting
nanocomposite is generally higher than their corre-
sponding zinc oxide. The surface area of zinc oxide and
4-ASA nanocomposite is 6.4 and 80.5 m2/g, respectively.
The BJH pore size distributions for zinc oxide and
4-ASA nanocomposite are shown in Figure 6B. All the
materials are of a mesoporous-type. The BJH pore size
distribution for 4-ASA nanocomposite shows an intense
peak at around 110 Å, compared to zinc oxide, which
show less intense broad peaks at around 10 and 90 Å.
The difference in peak values and pore volume values in
the pore size distribution of 4-ASA nanocomposite and
zinc oxide indicate the modification of the pure texture
which occurred when intercalation of 4-amino salicylic
acid took place, in agreement with the formation of the
nanocomposite. The BJH average pore diameter and pore






























ure of 4-amino salicylic acid with pristine zinc layered hydroxide,
posite at pH 7.4 (A) and pH 4.8 (B). Inset shows the release
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nanocomposite
Figure 7 (I) shows a release of 4-amino salicylic acid from
its physical mixture in both PBS solutions at pH 7.4 and
4.8. Generally, 4-amino salicylic acid was immediately re-
leased within the first five minutes, and reached at 80%
and 97%, at pH 7.4 and 4.8, respectively.
The release profiles of 4-amino salicylic acid from
the 4-ASA nanocomposite on exposure to either a pH
4.8 or pH 7.4 environments are shown in Figure 7 (II).
The release rate of 4-amino salicylic acid from the
nanocomposite is obviously depending on pH; release
at pH 7.4 is remarkably slower than that at pH 4.8.
The percentage release of 4-amino salicylic acid from
the nanocomposite reaches about 100% within about
1330 minutes when exposed to pH 4.8 compared to
only about 92% within about 8540 minutes at pH 7.4.
The difference in the release rate may be due to pos-
sible differences in mechanism [29,30]. At pH 7.4,
ZLH layers are more stable compared to pH 4.8. This
indicates that the ZLH layers in acidic media (pH 4.8)
dissolve more easily and the release occurs through
both the dissolution of ZLH layers and the diffusion.
On the other hand at pH 7.4 media, the release occurs
through a diffusion mechanism.
The release rate of 4-amino salicylic acid from its
nanocomposite was obviously very much slower than
that from the physical mixture, indicating that the
nanocomposite potentially can be used as a better alter-




















































Figure 8 Kinetics of control release fitting the data of 4-amino salicyl
pH 7.4 and 4.8 using pseudo-first, pseudo-second order kinetics andRelease kinetics of 4-amino salicylic acid from 4-ASA
nanocomposite
Usually, the release process of drug molecules from the
nanocomposite may be described using pseudo-first
order, pseudo-second order or parabolic diffusion kinetic
equations.
Pseudo-first-order kinetic equation may be represented
in the linear form as [31]
ln qeqtð Þ¼ ln qe–k1t
where qe and qt are the equilibrium release amount and
the release amount at any time (t), respectively. The k1
value can be obtained from the slope by plot ln(qe − qt)
against t.
Pseudo-second-order kinetic equation may be repre-
sented in the linear form as [32],
t=qt¼ 1=k2qe2þt=qe
The parabolic diffusion kinetic equation may be repre-
sented as [33],
1Mt=Moð Þ=t ¼ k t0:5 þ b
where Mo and Mt are the drug content remained in the
ZLH at release time 0 and t, respectively.
Using the above equations, it was found that the
pseudo-second order model is more satisfactory to de-
scribe the release kinetic process of 4-amino salicylic




































ic acid release from 4-ASA nanocomposite into PBS solutions at
parabolic diffusion model.
Table 3 Correlation coefficient (R2), and rate constants (k) obtained by fitting the data of 4-amino salicylic acid release




pseudo-first order pseudo-second order Parabolic diffusion model rate constant (k) (mg/min)
7.4 92 0.9339 0.9982 0.8961 3.9 × 10-5
4.8 100 0.8839 0.9999 0.5925 1.0 × 10-4
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http://journal.chemistrycentral.com/content/7/1/72of the fitting of 4-amino salicylic acid released from
4-ASA nanocomposite. At pH 4.8, the correlation coeffi-
cient (R2) and k2 values are 0.9999 and 1.0 × 10
-4 mg/min,
respectively and at pH 7.4, the corresponding value is
0.9982 and 3.9 × 10-5 mg/min, respectively. The re-
lease kinetic results are similar to the hippurate-zinc
layered hydroxide, ellagic acid-zinc layered hydroxide and
citirizine-zinc layered hydroxide synthesized by the direct
















































Figure 9 A-C Cytotoxicity Analysis: Cell viability (MTT assay) of 3T3-L1
hours. The data presented are mean ± SD of triplicate values.Cytotoxicity analysis of 4-amino salicylic acid (4-ASA) and
4-ASA nanocomposite
Figure 9 shows the effect of free 4-amino salicylic acid,
4-ASA nanocomposite and ZLH on cytotoxicity of 3T3
mouse fibroblast cells at different gradient concentra-
tions; 0.781, 1.562, 3.125, 6.25, 12.5, 25 and 50 μg/mL
and various time points; 24, 48 and 72 hours using MTT
assay. ZLH at concentrations from 0.781 to 12.5 μg/mL






exposed to various gradient concentrations at 24, 48 and 72
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http://journal.chemistrycentral.com/content/7/1/7248 hours duration of inhibition, but exposure with the
same concentration for 72 hours shows significant
cytotoxicity. Cells exposed to 25 and 50 μg/mL of
ZnO NPs for 48 hours showed 50% and > 90% reduction,
respectively in cells viability (Figure 9B) but not in 24 hours
exposure of nanocomposite (Figure 9A). In addition,
72 hours inhibition with ZLH nanocomposites, shows
stronger cytotoxicity when compared with 24 and 48 hours.
Conclusion
A nanocomposite of 4-amino salicylic-ZLH was obtained
by the intercalation of 4-amino salicylic acid anions into
zinc layered hydroxide using zinc oxide as starting mater-
ial. XRD technique was used to confirm the intercalation
4-ASA. The resulting nanocomposite has a basal spacing
of 24.0 Å, indicates that the guest adopted a bilayered ar-
rangement. FTIR study shows the presence of functional
groups of both 4-amino salicylic acid anions and inor-
ganic host. The thermal stability of intercalated 4-amino
salicylic acid anions were enhanced remarkably com-
pared to the pristine 4-amino salicylic acid anions whose
decomposition occurs at 227°C. The loading of 4-
aminosalicylic acid in the nanocomposite was estimated
to be about 16.9% (w/w). The release of 4-amino salicylic
acid anions from nanocomposite was found to occur in a
controlled manner, so the resulting material is suitable
for a controlled-release formulation. Based on prelimin-
ary cytotoxicity studies of the nanocomposite, more de-
tailed investigations are needed to elucidate the specific
cellular mechanism of toxicity. Further investigations on a
broader set of specific cell lines combined with an evalu-
ation of the detailed cellular mechanism of nanocomposite
cell interactions are also important. This investigation
helps to establish the suitability of pre-clinical model for
early toxicity assessment of the nanocomposite. The work
on the biocompatible sustained release formulation is a
step towards reduction in dosing frequency of the drugs
and subsequently enhances the patient compliance and
make the tuberculosis chemotherapy patient-friendly.
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